Kyleena (Levonorgestrel)

Levonorgestrel released from Kyleena thickens cervical mucus, impairs sperm motility and function, suppresses the growth of the uterine lining, and may inhibit ovulation. These actions together create conditions that prevent fertilisation and implantation.

Kyleena is supplied as a single intrauterine system containing 19.5 mg of levonorgestrel. The device is inserted by a qualified healthcare professional and releases a controlled amount of hormone over several years. The specific dosing regimen is determined by the prescriber.

Kyleena is contraindicated in pregnancy and is classified as pregnancy category X. It should not be used by women who are pregnant or planning to become pregnant. While breastfeeding is not an absolute contraindication, the prescriber should evaluate risks and benefits before use.

To order Kyleena, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with other levonorgestrel‑based IUS such as Mirena, Kyleena contains a lower total hormone load (19.5 mg vs. 52 mg) and is approved for a slightly shorter duration of up to five years. Both provide effective contraception, but Kyleena may be preferred for women seeking a lower hormone exposure.

Kyleena should be stored at ambient temperature, below 25 °C, in its original sealed packaging. Protect the device from moisture, direct sunlight and extreme temperatures to maintain its integrity until insertion.

Kyleena is inserted into the uterine cavity by a trained healthcare professional using a specialized inserter. The procedure is performed in a clinical setting under aseptic conditions, and the device remains in place to release levonorgestrel continuously for up to five years.

Serious risks include uterine perforation during insertion, pelvic inflammatory disease, ectopic pregnancy if contraception fails, and severe allergic reactions such as anaphylaxis. Patients should be monitored for signs of infection, abnormal bleeding, or severe abdominal pain.

Kyleena is contraindicated in women who are pregnant, have known or suspected uterine abnormalities (e.g., fibroids, congenital malformations), active pelvic infections, unexplained vaginal bleeding, or a history of breast cancer. It should also be avoided in individuals with hypersensitivity to levonorgestrel or any device components.